A subcutaneous vaccination strategy utilizing CpG oligodeoxynucleotide, OX40 monoclonal antibody (mAb), and tumor lysate at a distant location was developed using a mouse orthotopic GBM model. Here, TNFRSF4 is linked to neoplasm.